Sujentec Begins Exporting COVID-19 Rapid Test Kits to 20 Countries Including Europe... "Order Confirmed for 3 Million Kits"

[Asia Economy Reporter Yoo Hyun-seok] SuzenTech announced that it began exporting 50,000 kits of the first production batch of its novel coronavirus (COVID-19) antibody rapid diagnostic kits to 20 countries worldwide, including Italy, Spain, the Philippines, Indonesia, and Brazil, starting from the 31st. Although the initial plan was to export to six countries, due to the global spread of COVID-19, urgent supply requests poured in from multiple countries, expanding the export destinations to 20 countries.

SuzenTech's antibody rapid diagnostic kits allow for easy diagnosis using blood without the need for separate equipment or facilities. Accordingly, in most overseas countries lacking essential testing facilities, large equipment, and specialized clinical pathologists required for molecular diagnostic methods, SuzenTech's diagnostic kits are highly preferred.

In particular, SuzenTech's ‘SGTi-flex COVID-19 IgG/IgM’ kit simultaneously diagnoses IgG and IgM antibodies and does not require the ‘plasma separation’ process from fingertip blood or whole blood. Therefore, by simply dropping a single drop of blood onto the kit, COVID-19 infection status can be rapidly diagnosed within 10 minutes, leading to urgent supply requests from countries where COVID-19 infections are rapidly increasing.

Recently, as Chinese-made products supplied to Europe faced issues with quality and accuracy, awareness of SuzenTech’s highly accurate products has increased, resulting in supply requests from European governments.

A SuzenTech official stated, "More than 3 million kits have already been ordered, and as soon as production is completed, products are supplied mainly to distributors with verified distribution networks." He added, "Generally, long-term supply contracts are signed before supplying products, but due to the surge in demand for COVID-19 diagnostic kits, products are supplied by receiving advance payments according to production plans without supply contracts."

He continued, "Due to the surge in orders, production facility expansion is underway. Initially, we planned to produce and supply 3 million tests by the end of June, but the production schedule has been moved up to the end of May, and additional capacity expansion is also planned."

The United States, China, and the WHO recommend using antibody testing with blood alongside molecular diagnostics (PCR). Recently, as COVID-19 infections have surged in the United States and opinions have emerged emphasizing the importance of antibody rapid diagnostic kits to prevent further spread, SuzenTech is proceeding with FDA product registration for use in the U.S. and is negotiating product supply with state government authorities.